Exblifep (cefepime/enmetazobactam) / Allecra - LARVOL DELTA

Ceftazidime-avibactam plus aztreonam for extensively drug-resistant gram-negative infections in critically ill patients. (PubMed, J Crit Care) - "Ceftazidime-avibactam plus aztreonam combination demonstrated significant in vitro synergy against XDR pathogens with promising trends toward improved clinical outcomes in critically ill patients, representing a crucial salvage therapy option warranting larger randomized controlled trials."

Journal • Critical care • Infectious Disease • Pneumonia • Septic Shock

Nephrotoxicity of New Antibiotics: A Systematic Review. (PubMed, Toxics) - "The agents assessed included aztreonam/avibactam, cefepime/enmetazobactam, cefiderocol, ceftobiprole, contezolid, gepotidacin, imipenem/cilastatin/relebactam, lascufloxacin, lefamulin, levonadifloxacin, plazomicin, and sulbactam/durlobactam. There is a need for post-marketing studies to better characterize renal safety. Clinicians should remain vigilant and continue to monitor for and report renal-related adverse events."

Journal • Review

In-vitro activity of cefepime/enmetazobactam against extended spectrum beta-lactamases and/or ampC producing Enterobacterales and Pseudomonas aeruginosa collected across India. (PubMed, Diagn Microbiol Infect Dis) - "The findings of the present study retraites that the spectrum of coverage of cefepime/enmetazobactam is superior to that of TZP and similar to that of meropenem, emphasising the importance of cefepime/enmetazobactam as a carbapenem-sparing option."

Journal • Preclinical • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

In Vitro Activity of Cefepime-Enmetazobactam against Enterobacterales Isolated from Cancer Patients (ASM Microbe 2025) - "Isolates resistant to third-generation cephalosporins and isolates nonsusceptible to meropenem were screened for the presence of ß-lactamases. Cefepime/enmetazobactam showed excellent activity against most of the Enterobacterales isolates. Excellent activity was seen against third-generation cephalosporin resistant isolates. Cefepime/enmetazobactam exhibited higher activity than Piperacillin-tazobactam and Cefeperazone-sulbactam suggesting a good therapeutic alternative as compared with carbapenems against ESBL producers."

Preclinical • Infectious Disease • Oncology • Pneumonia

Is It Time to Finally Spare Carbapenems? In-Vitro Activity of Cefepime/Enmetazobactam Against ESBL-Producing and Cefepime Resistant Spice Organisms (ASM Microbe 2025) - "In all 110 isolates, FPE showed a 100% susceptibility to ESBL-producing and CEF resistant SPICE-organisms. This new combination demonstrated in-vitro activity against both ESBL-producing and SPICE organisms."

Preclinical • Infectious Disease • Pneumonia

In vitro activity of Cefepime/Enmetazobactam against Klebsiella pneumoniae carrying blaKPC allelic variants conferring resistance to Ceftazidime/Avibactam. (PubMed, Int J Antimicrob Agents) - No abstract available

Journal • Preclinical • Infectious Disease • Pneumonia

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics. (PubMed, Pathogens) - "During the last 2 years from the writing of this article, cefepime/enmetazobactam, aztreonam/avibactam, and sulbactam/durlobactam were approved for use in clinical practice. Aztreonam/avibactam is indicated for the treatment of adult patients who suffer from complicated intra-abdominal infections, complicated urinary tract infections including pyelonephritis, hospital-acquired pneumonia, and ventilator-associated pneumonia due to aerobic Gram-negative infections with limited therapeutic options. Sulbactam/durlobactam, a combination of 2 β-lactamase inhibitors, is indicated for the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia due to the Acinetobacter baumannii-calcoaceticus complex [including carbapenem-resistant Acinetobacter baumannii (CRAB) infections]."

Journal • Review • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

Diagnostic algorithm for the detection of carbapenemases and extended-spectrum β-lactamases in carbapenem-resistant Pseudomonas aeruginosa. (PubMed, Microbiol Spectr) - "We used the following BL-BLI combinations: ceftolozane-tazobactam (C-T), ceftazidime-avibactam, imipenem-relebactam (I-R), meropenem-vaborbactam, cefepime-enmetazobactam (C-E), and aztreonam-avibactam. This method is particularly valuable for laboratories lacking access to molecular diagnostics, as it provides a practical alternative for routine testing. By facilitating the early detection of resistant P. aeruginosa strains, this approach has the potential to improve patient outcomes, optimize antimicrobial therapy, and enhance global surveillance efforts against multidrug-resistant pathogens."

Journal • Infectious Disease

Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow. (PubMed, Expert Rev Anti Infect Ther) - "A literature search was performed on PubMed-MEDLINE (until December 2024) for retrieving available studies on cefepime-enmetazobactam, sulbactam-durlobactam, and cefepime-taniborbactam. Overall, old habits die hard and issues retrieved with licensed beta-lactams emerged also with novel BL/BLIc of tomorrow, potentially affecting their efficacy when used in real-world practice. Adopting appropriate corrective measures for overcoming these issues might increase the likelihood of preserving their efficacy in the future by minimizing the propensity risk of resistance development."

Clinical • Journal • Infectious Disease • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases

Cefepime/enmetazobactam as treatment for extended-spectrum-betalactamase producing Escherichia coli bloodstream infection in a septic patient with liver cirrhosis: a case report (ESCMID Global 2025) - No abstract available

Case report • Clinical • Fibrosis • Gastroenterology • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis

Microbiological outcome of eradication of cefepime/enmetazobactam vs piperacillin/tazobactam against most common Enterobacterales at test of cure; a posthoc analysis from the ALLIUM Phase 3 trial (ESCMID Global 2025) - No abstract available

P3 data • Retrospective data

Outcomes by MIC values for patients infected with Enterobacterales treated with cefepime/enmetazobactam or piperacillin/tazobactam for complicated urinary tract infections in the phase 3 ALLIUM trial (ESCMID Global 2025) - No abstract available

Clinical • P3 data • Infectious Disease • Nephrology

Cefepime/enmetazobactam for Gram-negative PJIs? A porcine study evaluating target tissue concentrations following intermittent short-term infusion and continuous infusion of a novel antibiotic combination (ESCMID Global 2025) - No abstract available

Gram negative • Preclinical • Infectious Disease

Impact of bacterial inoculum on the activity of cefepime and cefepime/enmetazobactam against AmpC-hyperproducing Enterobacter spp (ESCMID Global 2025) - No abstract available

Cefepime/enmetazobactam as a carbapenem-sparing alternative: activity against extended-spectrum beta-lactamase-producing Enterobacteriaceae, with or without carbapenemases (ESCMID Global 2025) - No abstract available

Effect of cefepime/enmetazobactam (FEP-META) versus ceftazidime/avibactam (CAZ-AVI) in combination with aztreonam (ATM) against clinical isolates resistant to different β-lactamase classes (ESCMID Global 2025) - No abstract available

Clinical • Combination therapy

Influence of outer membrane permeability and KPC amino acid variation on the activity of cefepime/enmetazobactam against KPC-producing Enterobacterales showing ceftazidime/avibactam resistance (ESCMID Global 2025) - No abstract available

Activity of cefepime/enmetazobactam in highly resistant Gram-negative bacteria in a tertiary care setting in Germany (ESCMID Global 2025) - No abstract available

Gram negative • Infectious Disease

In vitro efficacy of cefepime/enmetazobactam against AmpC beta-lactamase-producing Enterobacterales (ESCMID Global 2025) - No abstract available

Preclinical

In vitro activity of cefepime/enmetazobactam and comparators against ESBL and plasmid-AmpC-producing Enterobacterales (ESCMID Global 2025) - No abstract available

Preclinical

Evaluation of cefepime/enmetazobactam efficacy against BLEE + OXA 48 resistant strains (ESCMID Global 2025) - No abstract available

Clinical

Activity of the novel beta-lactam/beta-lactamase inhibitor combination cefepime/enmetazobactam against Acinetobacter spp. (ESCMID Global 2025) - No abstract available

IPT17 - Physicochemical stability of cefepime/emmetazobactam in medical devices for continuous infusion. Is it possible to use it in OPAT? (ESCMID Global 2025) - "Stability data are required for continuous infusion. At Advanz we have carried out a pre-clinical development to generate physicochemical stability data on different medical devices and at different conditions to understand the potential use of cefepime-enmetazobactam in continuous infusions and for it use in OPAT."

In vitro activity of cefepime/enmetazobactam against clinical isolates of Enterobacterales in Portugal: A multicentre retrospective study (ESCMID Global 2025) - No abstract available

Preclinical • Retrospective data

'In vitro activity of cefepime-enmetazobactam on carbapenem resistant Gram negatives' - Author's reply. (PubMed, Clin Microbiol Infect) - No abstract available

Journal • Preclinical • Infectious Disease